Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/4/2007 First Published: 3/1/1995


1.		Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Under 80				NCI				CAN-NCIC-PR3 CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3

Last Modified: 1/28/2004


2.		Phase III Study of Chemo/Hormonal Therapy vs Androgen Ablation Alone as Initial Therapy in Patients With Unresectable/Metastatic Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				no age specified				NCI				MDA-DM-95231 NCI-G96-1044, NCT00002855

Last Modified: 2/23/2007 First Published: 1/1/1999


3.		Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				CAN-NCIC-PR7 SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7

Last Modified: 6/1/1989


4.		Phase III Randomized Double-Blind Trial of Antiandrogen Therapy with Anandron plus the LHRH Agonist Zoladex vs Placebo in Patients with Unresectable Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				postpubertal								EORTC-40861

Last Modified: 2/1/1988


5.		Phase III Randomized Comparison of Leuprolide/Anandron vs Leuprolide/Placebo in Patients with Stage D2 Carcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				40 to 85								FCCC-86814 NCI-V87-0282

Last Modified: 11/13/2007 First Published: 8/1/2000


6.		Phase II Randomized Study of Vaccine Containing Recombinant Vaccinia-Prostate-Specific Antigen (PSA) Admixed With rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine, Sargramostim (GM-CSF), and Interleukin-2 Versus Nilutamide Alone in Patients With Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCI-00-C-0137 MB-NAVY-99-04, NCI-T99-0097, T99-0097, NCT00020254

Last Modified: 6/10/2005 First Published: 1/1/2002


7.		Phase II Study of Early Estramustine, Etoposide, and Paclitaxel With Combined Androgen Blockade Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 18				NCI				SWOG-S0032 S0032, NCT00028769

First Published: 3/24/2004


8.		Phase II Randomized Study of Combined Androgen Ablation With Versus Without Adjuvant Docetaxel and Estramustine in Patients With Androgen-Dependent Recurrent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MDA-DM-99224

Last Modified: 1/31/2008 First Published: 7/24/2007


9.		Phase I Study of Limited Androgen Ablation and Antiandrogen Therapy Followed by Temsirolimus in Patients With Biochemically Relapsed Prostate Cancer After Prostatectomy and/or Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Not specified				NCI				MDA-2007-0025 7862, 2007-0025, NCT00512668

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute